Search

Your search keyword '"For The Mint Study Group"' showing total 4 results
Start Over Author "For The Mint Study Group"
4 results on '"For The Mint Study Group"'

1. Changes in HPV16/18 Prevalence among Unvaccinated Women with Cervical Intraepithelial Neoplasia in Japan: Assessment of Herd Effects following the HPV Vaccination Program

Author

Mamiko Onuki, Kasumi Yamamoto, Hideaki Yahata, Hiroyuki Kanao, Koji Horie, Katsuyuki Konnai, Ai Nio, Kazuhiro Takehara, Shoji Kamiura, Naotake Tsuda, Yuji Takei, Shogo Shigeta, Hidekatsu Nakai, Hiroyuki Yoshida, Takeshi Motohara, Tatsuya Kato, Keiichiro Nakamura, Junzo Hamanishi, Nobutaka Tasaka, Mitsuya Ishikawa, Nobuhiro Kado, Yusuke Taira, Mayuyo Mori, Takashi Iwata, Fumiaki Takahashi, Iwao Kukimoto, Hiroyuki Yoshikawa, Nobuo Yaegashi, Koji Matsumoto, and for the MINT Study Group

Subjects
adenocarcinoma in situ, cervical cancer, cervical intraepithelial neoplasia, human papillomavirus, vaccination, Medicine
Abstract

Since the human papillomavirus (HPV) vaccination program for Japanese girls aged 12–16 years began in 2010, vaccination uptake has been low in women born before 1993 but high (approximately 70%) in those born during 1994–1999. We previously compared the prevalence of vaccine types HPV16 and HPV18 in cervical intraepithelial neoplasia grade 1–3 (CIN1–3) or adenocarcinoma in situ (AIS) between vaccinated and unvaccinated cohorts and found direct protection effects among vaccinated women in Japan. In this study, we focused on changes in HPV16/18 prevalence among “unvaccinated” cohorts with CIN/AIS. We analyzed HPV16/18 prevalence among 5051 unvaccinated women aged trend = 0.03) and CIN2–3/AIS (62.5–36.4%, Ptrend = 0.07) among women aged p = 0.04). Significant reduction in HPV16/18 prevalence among young unvaccinated women with CIN1 and CIN2–3/AIS suggests herd effects of HPV vaccination in Japan.

Published
2022
Full Text
View/download PDF

2. Changes in HPV16/18 Prevalence among Unvaccinated Women with Cervical Intraepithelial Neoplasia in Japan: Assessment of Herd Effects following the HPV Vaccination Program

Author

Mamiko, Onuki, Kasumi, Yamamoto, Hideaki, Yahata, Hiroyuki, Kanao, Koji, Horie, Katsuyuki, Konnai, Ai, Nio, Kazuhiro, Takehara, Shoji, Kamiura, Naotake, Tsuda, Yuji, Takei, Shogo, Shigeta, Hidekatsu, Nakai, Hiroyuki, Yoshida, Takeshi, Motohara, Tatsuya, Kato, Keiichiro, Nakamura, Junzo, Hamanishi, Nobutaka, Tasaka, Mitsuya, Ishikawa, Nobuhiro, Kado, Yusuke, Taira, Mayuyo, Mori, Takashi, Iwata, Fumiaki, Takahashi, Iwao, Kukimoto, Hiroyuki, Yoshikawa, Nobuo, Yaegashi, Koji, Matsumoto, and For The Mint Study Group

Subjects
Pharmacology, Infectious Diseases, Drug Discovery, Immunology, Pharmacology (medical), adenocarcinoma in situ, cervical cancer, cervical intraepithelial neoplasia, human papillomavirus, vaccination, female genital diseases and pregnancy complications
Abstract

Since the human papillomavirus (HPV) vaccination program for Japanese girls aged 12–16 years began in 2010, vaccination uptake has been low in women born before 1993 but high (approximately 70%) in those born during 1994–1999. We previously compared the prevalence of vaccine types HPV16 and HPV18 in cervical intraepithelial neoplasia grade 1–3 (CIN1–3) or adenocarcinoma in situ (AIS) between vaccinated and unvaccinated cohorts and found direct protection effects among vaccinated women in Japan. In this study, we focused on changes in HPV16/18 prevalence among “unvaccinated” cohorts with CIN/AIS. We analyzed HPV16/18 prevalence among 5051 unvaccinated women aged

Published
2021

3. Reduction in HPV16 and HPV18 Prevalence Among Young Women with Low- and High-Grade Cervical Lesions Following the Japanese HPV Vaccination Program: 6-Year Analysis of the MINT Study

Author

Koji Matsumoto, Nobuo Yaegashi, Takashi Iwata, Kasumi Yamamoto, Yoichi Aoki, Masao Okadome, Kimio Ushijima, Shoji Kamiura, Kazuhiro Takehara, Koji Horie, Nobutaka Tasaka, Kenzo Sonoda, Yuji Takei, Katsuyuki Konnai, Hidetaka Katabuchi, Keiichiro Nakamura, Mitsuya Ishikawa, Hidemichi Watari, Hiroyuki Yoshida, Noriomi Matsumura, Hidekatsu Nakai, Shogo Shigeta, Fumiaki Takahashi, Kiichiro Noda, Hiroyuki Yoshikawa, and MINT Study Group

Subjects
medicine.medical_specialty, Invasive cervical cancer, business.industry, Incidence (epidemiology), Hpv vaccination, Cervical intraepithelial neoplasia, medicine.disease, Clinical trial, Vaccination, Internal medicine, Medicine, business, Adverse effect, Research review
Abstract

Background The Japanese government began the national human papillomavirus (HPV) vaccination program for girls aged 12-16 years in 2010 but withdrew its recommendation in 2013 because of potential adverse effects, leading to drastically reduced vaccination uptake. Methods To evaluate the population-level impact of HPV vaccination implemented for only 3 years in Japan, women aged 20 years. Older adolescents who skipped routine HPV vaccination owing to the Japanese government's suspension of recommendation may benefit from receiving catch-up HPV vaccination before they reach age 20 years. Clinical Trial Registration: This study was registered in the UMIN Clinical Trials Registry as UMIN000008891. Funding Statement: The Foundation for Advancement of International Science (FAIS) and the Japanese Agency of Medical Research and Development (AMED) (grant number: 19fk0108098). Declaration of Interests: Koji Matsumoto received lecture fees from HOLOGIC Japan, Inc. and MSD K.K., and research grants from MSD K.K. Kimio Ushijima received lecture fees from MSD K.K. Ethical Approval Statement: Institutional ethical and research review boards of the participating institutions have approved the study protocol.

Published
2019
Full Text
View/download PDF

4. Changes in HPV16/18 Prevalence among Unvaccinated Women with Cervical Intraepithelial Neoplasia in Japan: Assessment of Herd Effects following the HPV Vaccination Program.

Author

Onuki M, Yamamoto K, Yahata H, Kanao H, Horie K, Konnai K, Nio A, Takehara K, Kamiura S, Tsuda N, Takei Y, Shigeta S, Nakai H, Yoshida H, Motohara T, Kato T, Nakamura K, Hamanishi J, Tasaka N, Ishikawa M, Kado N, Taira Y, Mori M, Iwata T, Takahashi F, Kukimoto I, Yoshikawa H, Yaegashi N, Matsumoto K, and For The Mint Study Group

Abstract

Since the human papillomavirus (HPV) vaccination program for Japanese girls aged 12-16 years began in 2010, vaccination uptake has been low in women born before 1993 but high (approximately 70%) in those born during 1994-1999. We previously compared the prevalence of vaccine types HPV16 and HPV18 in cervical intraepithelial neoplasia grade 1-3 (CIN1-3) or adenocarcinoma in situ (AIS) between vaccinated and unvaccinated cohorts and found direct protection effects among vaccinated women in Japan. In this study, we focused on changes in HPV16/18 prevalence among "unvaccinated" cohorts with CIN/AIS. We analyzed HPV16/18 prevalence among 5051 unvaccinated women aged <40 years, newly diagnosed with CIN/AIS during 2012-2021 for time trends. Declining trends in HPV16/18 prevalence over 9 years were observed in CIN1 (36.0-10.0%, P trend = 0.03) and CIN2-3/AIS (62.5-36.4%, P trend = 0.07) among women aged <25 years. HPV16/18 prevalence in CIN1 and CIN2-3/AIS diagnosed at age 20-24 years was lower in 1994-1999 birth cohorts compared with 1988-1993 birth cohorts (4.5% vs. 25.7% for CIN1 and 40.0% vs. 58.1% for CIN2-3/AIS, both p = 0.04). Significant reduction in HPV16/18 prevalence among young unvaccinated women with CIN1 and CIN2-3/AIS suggests herd effects of HPV vaccination in Japan.

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results